Publicis Deepens Influencer Marketing Push With Deal for Captiv8
Publicis PUB -0.23%decrease; red down pointing triangle Groupe said it is buying Captiv8, a platform that connects influencers and brands, in a deal that steps up its push into influencer-marketing services.
The acquisition is valued at $150 million, according to a person familiar with the terms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Equinor and Centrica Ink $27 Billion Natural Gas Supply Deal for U.K.
Equinor ASA (NYSE:EQNR) has signed a new long-term deal with U.K. energy company Centrica, worth roughly £20 billion ($27.1 billion), to supply natural gas to the U.K. over the next decade. Starting October 1, the agreement is based on current market prices and will provide about 10% of the country's annual gas needs. Despite efforts to cut back on fossil fuels, around 70% of U.K. homes still rely on gas for heating, and gas power plants contribute roughly 25% of the nation's electricity. Under the agreement, Equinor ASA (NYSE:EQNR) will deliver about 5 billion cubic meters of gas per year, compared to the U.K.'s 2024 total demand of 55.8 billion cubic meters. Equinor ASA (NYSE:EQNR) Chief Executive Anders Opedal made the following statement: 'This agreement will continue to support the U.K.'s energy security with reliable gas supplies from the Norwegian continental shelf.' This deal replaces an earlier 10-year contract between the two companies that began in 2015 and ends in 2025. Last year, the U.K. imported nearly two-thirds of its gas supply, with Norway accounting for half of those imports, especially after Russian gas exports to Europe dropped following the 2022 invasion of Ukraine. EQNR has surged by over 4% in the past month. While we acknowledge the potential of EQNR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Investing in a SIPP? These are the 5 most popular active funds
Building a large nest egg with a Self-Invested Personal Pension (SIPP) can be quite a daunting task. Picking individual stocks requires a more hands-on approach and risk-taking that not every investor is comfortable with. Instead, most retirement investors seeking to beat the market tend to rely on actively managed investment funds. There's a lot to like about taking this approach to investing. All the hassle of picking stocks and portfolio management is handed off to a professional. And thanks to insights from Hargreaves Lansdown, we know which funds have proven to be the most popular among British SIPP investors. The top five most popular actively managed funds bought by SIPP investors are: HL Multi-Index Moderately Adventurous Royal London Short-Term Money Market Baillie Gifford American Fund B Vanguard Sterling Short-Term Money Market Fidelity Cash Fund W Despite their popularity, these active funds haven't been stellar performers of late. In the last 12 months, all five have generated a positive return. Yet the best performance hasn't been all that groundbreaking. The average return across all five is just 8.3% before management fees. Baillie Gifford American is the standout performer, achieving an impressive 21% gain since June last year. But when zooming out the last five years, investors have only reaped a 6.2% total return. By comparison, the FTSE 100 over the same period is up by 35%. And index tracker funds charge significantly lower fees. Actively managed funds are often criticised for their lack of consistent market-beating returns once managers take their fee. And index funds, on average, tend to outperform active funds. But sadly, these also have the downside of closing the door to any possibility of market-beating returns. This is why prudent stock picking, in my opinion, continues to be the best option for long-term DIY investors. Take a look at one of the FTSE 100's largest companies – RELX (LSE:REL). This is a mature data analytics provider to critical sectors and departments such as science, law, business, healthcare, and risk management, among others. Revenue and earnings growth may not be very explosive. However, the firm's ability to consistently generate free cash flow from its subscription revenue model, paired with the rapid integration of artificial intelligence (AI), has enabled the business to outperform. And this has translated into a near-110% return since June 2020 before even accounting for dividends – more than three times a passive index fund. Of course, not all UK stocks have performed as strongly during this period. And even a seemingly high-quality company like RELX has its weak spots. Free AI tools like ChatGPT and Gemini already offer competing research analysis solutions. And if RELX's own AI tools can't stay ahead of the innovation curve, it may struggle to maintain its pricing power in the long run. There's also a risk of national budget sensitivity to consider. Many of RELX's customers are universities and research groups reliant on government grants and funding. So any cuts to public spending can potentially throw a spanner into the firm's growth plans. Despite these risks, RELX's outlook still looks promising, in my opinion. Therefore, investors may want to consider taking a closer look at this business as a potential long-term addition to their own SIPPs. The post Investing in a SIPP? These are the 5 most popular active funds appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended RELX. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Cellebrite DI Ltd. (CLBT) to Acquire Corellium
Cellebrite DI Ltd. (NASDAQ:CLBT) makes a move to acquire Corellium, a developer of Arm-based virtualization software. The transaction is valued at $170 million in cash, plus up to $30 million in contingent consideration, and reflects the company's deepening footprint across the mobile security and digital intelligence spectrum. A female engineer in a datacenter, wearing a headset, monitoring digital data. The acquisition of Corellium introduces mobile vulnerability research tools, smart device DevSecOps, and virtual device testing, thereby complementing Cellebrite DI Ltd. (NASDAQ:CLBT)'s plan to expand beyond traditional digital investigations. The company's Interim CEO, Thomas E. Hogan, has further made the following statement. 'The combination of our respective talent and IP changes the game in the efficient securing and analysis of all Arm-based devices.' Cellebrite DI Ltd. (NASDAQ:CLBT)'s shares opened at $16.85 today. The acquisition is pending regulatory approval and is expected to close this summer. This timing stands close to the company's plans to announce the appointment of the permanent CEO. Though the stock's monthly performance has declined by 11.94%, its weekly performance has seen an uptick of 2.18%, potentially influenced by the acquisition buzz. The Israeli company, Cellebrite DI Ltd. (NASDAQ:CLBT), established under the telecommunications and digital intelligence industries, offers advanced digital forensics tools to law enforcement, intelligence agencies, and enterprises worldwide. With a market capitalization of $4.06 billion, the company is best known for its flagship product series, Cellebrite UFED. While we acknowledge the potential of CLBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Sign in to access your portfolio
